logo

ADCT

ADC Therapeutics·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ADCT fundamentals

ADC Therapeutics (ADCT) released its earnings on Nov 10, 2025: revenue was 16.43M (YoY -11.00%), missed estimates; EPS was -0.19 (YoY +32.14%), beat estimates.
Revenue / YoY
16.43M
-11.00%
EPS / YoY
-0.19
+32.14%
Report date
Nov 10, 2025
ADCT Earnings Call Summary for Q3,2025
  • Stable ZYNLONTA revenue: $15.8M Q3 2025, maintaining third-line DLBCL market position.
  • Pipeline momentum: LOTIS-5 Phase III data H1 2026, LOTIS-7 interim update Q4 2025 with 93.3% ORR.
  • Peak revenue vision: $600-1B U.S. for ZYNLONTA, driven by second-line DLBCL ($200-300M) and MZL ($100-200M).
  • Financial strength: $292M cash post-PIPE, 2028+ runway, 12% YoY expense reduction.
EPS
Revenue

Revenue & Expenses

ADCT has released its 2025 Q3 earnings report, with revenue of 16.43M, reflecting a YoY change of -11.03%, and net profit of -40.97M, showing a YoY change of 6.83%. The Sankey diagram below clearly presents ADCT's revenue sources and cost distribution.

Key Indicators

ADC Therapeutics (ADCT) key financial stats and ratios, covering profitability, financial health, and leverage.
ADC Therapeutics (ADCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
ADC Therapeutics (ADCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
ADC Therapeutics (ADCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does ADC Therapeutics (ADCT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track ADC Therapeutics (ADCT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield